Adjuvants for Enhancing the Immunogenicity of Whole Tumor Cell Vaccines

Unknown

(2016)   IMMUNOLOGICAL REVIEWS

A CpG-loaded tumor cell vaccine induces antitumor CD4+ T cells that are effective in adoptive therapy for large and established tumors

(2010) M. J. Goldstein et al.   BLOOD

Herpes virus oncolytic therapy reverses tumor immune dysfunction and facilitates tumor antigen presentation

(2010) Fabian Benencia et al.   CANCER BIOLOGY & THERAPY

Durable Complete Response of Refractory, Progressing Metastatic Melanoma After Treatment with a Patient-Specific Vaccine

(2010) Robert O. Dillman et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers

(2010) Melissa A. Geller et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Monophosphoryl lipid A plus IFNγ maturation of dendritic cells induces antigen-specific CD8+ cytotoxic T cells with high cytolytic potential

(2010) Anja ten Brinke et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Current status of immunological therapies for prostate cancer

(2010) Emmanuel S Antonarakis et al.   CURRENT OPINION IN UROLOGY

Human CD141+(BDCA-3)+dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens

(2010) Sarah L. Jongbloed et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Adjuvants for cancer vaccines

(2010) Thomas W. Dubensky et al.   SEMINARS IN IMMUNOLOGY

Whole tumor antigen vaccines

(2010) Cheryl Lai-Lai Chiang et al.   SEMINARS IN IMMUNOLOGY

Targets of Protective Tumor Immunity

(2009) Glenn Dranoff   Annals of the New York Academy of Sciences

Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML)

(2009) I. M. Borrello et al.   BLOOD

In situ Stimulation of CD40 and Toll-like Receptor 3 Transforms Ovarian Cancer-Infiltrating Dendritic Cells from Immunosuppressive to Immunostimulatory Cells

(2009) U. K. Scarlett et al.   CANCER RESEARCH

Endothelin B Receptor, a New Target in Cancer Immune Therapy

(2009) L. E. Kandalaft et al.   CLINICAL CANCER RESEARCH

Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF

(2009) Luigi Dolcetti et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

A phase II study of GM-CSF and rIFN-γ1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer

(2009) Kathleen M. Schmeler et al.   GYNECOLOGIC ONCOLOGY

Consolidation strategies in ovarian cancer: Observations for future clinical trials

(2009) Paul Sabbatini et al.   GYNECOLOGIC ONCOLOGY

Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian tumors

(2009) Maria R. Roche et al.   GYNECOLOGIC ONCOLOGY

Treatment with LL-37 Peptide Enhances Antitumor Effects Induced by CpG Oligodeoxynucleotides Against Ovarian Cancer

(2009) Chi-Mu Chuang et al.   HUMAN GENE THERAPY

Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial

(2009) Ninke Leffers et al.   INTERNATIONAL JOURNAL OF CANCER

Prolonged Survival of Dendritic Cell–Vaccinated Melanoma Patients Correlates With Tumor-Specific Delayed Type IV Hypersensitivity Response and Reduction of Tumor Growth Factor β-Expressing T Cells

(2009) Mercedes N. López et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma

(2009) Ranjana Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

Hypochlorous Acid: A Natural Adjuvant That Facilitates Antigen Processing, Cross-Priming, and the Induction of Adaptive Immunity

(2009) Z. M. Prokopowicz et al.   JOURNAL OF IMMUNOLOGY

Ascites Regression and Survival Increase in Mice Bearing Advanced-stage Human Ovarian Carcinomas and Repeatedly Treated Intraperitoneally With CpG-ODN

(2009) Michelandrea De Cesare et al.   JOURNAL OF IMMUNOTHERAPY

Eradication of Ovarian Tumor Xenografts by Locoregional Administration of Targeted Immunotherapy

(2008) M. De Cesare et al.   CLINICAL CANCER RESEARCH

Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission

(2008) C. S.M. Diefenbach et al.   CLINICAL CANCER RESEARCH

Oxidation of Ovarian Epithelial Cancer Cells by Hypochlorous Acid Enhances Immunogenicity and Stimulates T Cells that Recognize Autologous Primary Tumor

(2008) C. L-L. Chiang et al.   CLINICAL CANCER RESEARCH

An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma

(2008) R. Dummer et al.   CLINICAL CANCER RESEARCH

Clinical investigations of Toll-like receptor agonists

(2008) Thomas Meyer et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells

(2008) Mirjam Kool et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Results of the First Phase I/II Clinical Vaccination Trial With Direct Injection of mRNA

(2008) Benjamin Weide et al.   JOURNAL OF IMMUNOTHERAPY

A Multipeptide Vaccine is Safe and Elicits T-cell Responses in Participants With Advanced Stage Ovarian Cancer

(2008) Kimberly A. Chianese-Bullock et al.   JOURNAL OF IMMUNOTHERAPY

Whole tumor antigen vaccination using dendritic cells: Comparison of RNA electroporation and pulsing with UV-irradiated tumor cells

(2008) Fabian Benencia et al.   Journal of Translational Medicine

Phase I Clinical Trial of Autologous Ascites-derived Exosomes Combined With GM-CSF for Colorectal Cancer

(2008) Shengming Dai et al.   MOLECULAR THERAPY

Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants

(2008) Stephanie C. Eisenbarth et al.   NATURE

TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-β

(2008) Jonathan C Kagan et al.   NATURE IMMUNOLOGY

TLR7 and TLR8 as targets in cancer therapy

(2008) M P Schön et al.   ONCOGENE

The Use of TLR7 and TLR8 Ligands for the Enhancement of Cancer Immunotherapy

(2008) E. L. J. M. Smits et al.   ONCOLOGIST

The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine

(2008) C. Trumpfheller et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

(2008) F. S. Hodi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Antigens for cancer immunotherapy

(2008) Michelle A. Neller et al.   SEMINARS IN IMMUNOLOGY

Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice

(2008) Andreas Wack et al.   VACCINE

A clinical grade poly I:C-analogue (Ampligen®) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro

(2008) H. Navabi et al.   VACCINE

The potency of the adjuvant, CpG oligos, is enhanced by encapsulation in PLG microparticles

(2007) Padma Malyala et al.   JOURNAL OF PHARMACEUTICAL SCIENCES